Silevertinib Data Approach: Binary Decision for BDTX

What happened

Black Diamond Therapeutics' equity is now almost entirely tied to silevertinib, a Phase 2 EGFR inhibitor for NSCLC and GBM. Early clinical data show encouraging ORR (~36-42%) and brain penetration, but the stock remains highly binary. The upcoming 2026 durability data and FDA feedback on registrational pathway are the decisive swing factors. Without pivotal trials underway and with intense competition, the risk/reward is speculative. The Servier deal provides runway into 4Q27, but the story hinges on silevertinib's performance.

Implication

For a core position, wait for Phase 2 data demonstrating durable responses and a feasible FDA registrational path. If data are competitive and FDA feedback is clear, consider a POTENTIAL BUY; if not, the stock is likely a sell given dilution risk and competitive pressure.

Thesis delta

The thesis shifts from early promise of silevertinib's broad mutation coverage and CNS penetration to a focus on durability and regulatory feedback as the critical catalysts. The previous watch-and-wait stance is now more urgent as the 4Q25-1H26 data will likely determine whether the asset has a viable path or the story unravels.